Chronic myelomonocytic leukemia following prolonged alkylating agent therapy for multiple myeloma

Int J Hematol. 1994 Dec;60(4):263-5.

Abstract

A 35-year-old male presented with chronic myelomonocytic leukemia (CMMoL) after 6.5 years of alkylating agent therapy for IgG-kappa type multiple myeloma. The total dose of melphalan was 0.648 g. CMMoL was stable with weekly injection of alpha-interferon for one year. Thereafter, monocytosis and thrombocytopenia aggravated, and the patient died of disseminating intravascular coagulation. Prolonged drug therapy can induce CMMoL, as well as other myelodysplastic syndromes.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Disseminated Intravascular Coagulation / chemically induced
  • Humans
  • Leukemia, Myelomonocytic, Chronic / chemically induced*
  • Male
  • Melphalan / adverse effects*
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Myelodysplastic Syndromes / chemically induced
  • Neoplasms, Second Primary / chemically induced*

Substances

  • Melphalan